A Letter to Our Readers

Letter to Readers |
October 12, 2016

A Letter to Our Readers

  1. Allan S. Brett, MD, Editor-in-Chief, NEJM Journal Watch

A farewell to the outgoing Editor-in-Chief and a welcome to the incoming Editor-in-Chief

  1. Allan S. Brett, MD, Editor-in-Chief, NEJM Journal Watch

Dear Readers,

After nearly a decade of outstanding leadership, Larry Baddour, MD, is stepping down as Editor-in-Chief of NEJM Journal Watch Infectious Diseases. Dr. Baddour has served as Editor-in-Chief since 2007 and has capably led the publication during the past decade. On behalf of the NEJM Journal Watch Infectious Diseases editorial board and NEJM Group, we'd like to express our gratitude to Dr. Baddour for his steady leadership, his clinical and editorial expertise, and his commitment to you, our readers.

At the same time, we are pleased to announce the appointment of Richard T. Ellison III, MD, as the new Editor-in-Chief of NEJM Journal Watch Infectious Diseases. Dr. Ellison has served as Deputy Editor and written for the publication since its inception in 1998. He is Professor of Medicine, Microbiology & Physiological Systems, in the Division of Infectious Diseases and Immunology at the University of Massachusetts Medical School. His research interests include nosocomial infections, HIV disease, infection control, and control and treatment of infections caused by antibiotic-resistant bacteria.

With Dr. Ellison and the NEJM Journal Watch Infectious Diseases editors, we're committed to continuing to identify, summarize, and interpret the most important research and guidelines, with an eye toward informing clinical practice. We trust that you'll continue to find NEJM Journal Watch an essential part of your professional lives. Please don't hesitate to contact us if you have any ideas or suggestions on how we might improve our publication.

Allan S. Brett, MD, Editor-in-Chief, NEJM Journal Watch

Editor Disclosures at Time of Publication

  • Disclosures for Allan S. Brett, MD, Editor-in-Chief, NEJM Journal Watch at time of publication Nothing to disclose

Reader Comments (1)

STEVEN BERMAN

Thank you

Your Comment

(will not be published)

Filtered HTML

  • Allowed HTML tags: <a> <em> <strong> <cite> <blockquote> <code> <ul> <ol> <li> <dl> <dt> <dd>
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Do you have any conflict of interest to disclose?
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

* Required

Reader comments are intended to encourage lively discussion of clinical topics with your peers in the medical community. We ask that you keep your remarks to a reasonable length, and we reserve the right to withhold publication of remarks that do not meet this standard.

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.